Program Book

gene expression profile of melanocytic uveal tumour cells obtained by FNAB.
Since then, virtually all FNABs of clinically diagnosed uveal melanomas were
simultaneously confirmatory, prognostic (cytology), and investigational for GEP
while those performed on tumours diagnosed as nevus versus melanoma were
simultaneously diagnostic, prognostic (cytology), and investigational for GEP.
In late 2009, the COOG study validated the prognostic value of GEP of large and
medium size uveal melanomas. A commercial laboratory (Castle Biosciences,
Inc.) acquired the GEP test and all biopsies of similar tumours performed since
then have been regarded as prognostic simultaneously for GEP and cytology.
Conclusions. Indications for performing FNABs on solid intraocular tumours in
this series changed substantially over the years. The FNAB method employed in
a given case depends on indication for biopsy, timing of biopsy, and specimen
size for a successful result.
Financial disclosure. Research to Prevent Blindness, New York, NY, USA, and Quest for Vision
Fund, University of Cincinnati, Cincinnati, OH. USA
204 UM13
PROSPECTIVE EVALUATION OF A GENE EXPRESSION
PROFILE PROGNOSTIC ASSAY FOR UVEAL MELANOMA
IN 514 PATIENTS
J. William Harbour, Michael D. Onken, Lori A. Worley, James J. Augsburger,
Zelia M Correa, Devron H. Char, Eric Nudleman, Thomas M. Aaberg,
Jr., Michael M. Altaweel, David S. Bardenstein, Paul T. Finger, Brenda
L. Gallie, George J. Harocopos, Peter G. Hovland, Hugh D. McGowan,
Tatyana Milman, Prithvi Mruthyunjaya, E. Rand Simpson, Morton E.
Smith, David J. Wilson, William J. Wirostko (harbour@vision.wustl.edu)
Washington University, University of Cincinnati, Tumori Foundation,
Michigan State University, University of Wisconsin, Case Western
Reserve University, New York Eye Cancer Centre, Colorado Retina
Associates, University of Toronto, New York Eye and Ear Infirmary, Duke
University, Oregon Health & Science University, Medical College of
Wisconsin
Purpose. A 15 gene expression profiling (GEP) assay was developed to assign
primary uveal melanomas to prognostic subgroups: class 1 (low metastatic
risk) and class 2 (high metastatic risk). This study evaluated the prognostic
performance of the 15-gene assay in a prospective, multicenter study.
Methods. 514 patients with uveal melanoma were enrolled in a prospective,
12-center study. Tumours were assigned to class 1 or class 2. 293 of the
samples were also analyzed for chromosome 3 status using a single
nucleotide polymorphism assay. Patients were managed for their primary
tumour and monitored for metastasis.
Results. The GEP was class 1 in 308 cases (60.0%) and class 2 in 206 cases
(40.0%). Of the class 1 cases, 308 (87.0%) were class 1A and 67 (13.0%)
were class 1B. Metastasis was detected in 2 (0.8%) class 1A patients, 7
(10.4%) class 1B, and 61 (29.8%) class 2 (P